Having trouble viewing the email? click here.

2nd Edition / December 2017

As promised, and after the “soft launch” of our first Newsletter in October this year, we continue our ongoing update of news and events within the eHealth Ventures incubator and portfolio.

We had plenty of activity over the past few months, and would like to share. Send input, comments, ideas etc. – we are always happy to hear from you - info@ehealthventures.com and also at our new, super-cool domain (we will publish a separate story on how we got it): info@ehv.health

The eHealth Ventures Team.

4 new companies start activity within the eHV incubator
After an extremely busy period of screening, negotiating and preparing applications for the Israeli Innovation authority (IIA), we are very happy to announce that 4 companies have been accepted into the eHV incubator (THE digital health incubator) and have officially started operations:
Allerguard Logo
Allerguard - Personal Allergy Detector (Peanut) for consumers
Derma Detect logo
Derma Detect - AI based dermatology diagnostics
OsteoSee - Bone Density Measurement as screening and monitoring tool
Mind's Eye Logo
Mind’s Eye – Objective ADHD Diagnostics via detection and measurement of a unique bio-marker


Needless to say, we are proud of all 4 companies and their teams and wish the best of success to all.

eHealth Ventures VP BD, Ophir Shahaf, a speaker at the Open Innovations Forum held in Moscow on October 2017

Following an executive order from the Russian President earlier this year, some of the leading Russian government-controlled companies have established CVC (Corporate Venture Capital) entities.

As a relatively new player in the innovation ecosystem, many questions are being asked by these players, as to the operation of such entities, their interaction with VCs and other investing parties and the focusing of the innovation so that it would not only generate a return but also add to the pipeline and strategic goals of the corporation.

Adv. Shahaf presented to a panel of investors and government entities, led by Mr. Arkady Dvorkovich, Deputy Prime Minister of Russia and Chairman of the Russian Railroad Company. The presentation was titled: “New Investment Models for the Digital Era” and it focused on the unique platform created by the eHV incubator - working with several very different types of investors:                                              Maccabi - a leading Israel HMO (Payer), The Cleveland Clinic - a Major US Medical Center (Provider), the Israeli Innovation Authority - leveraging state funding, Amgen Ventures - a multinational CVC, Medison - an Israeli drug distributor, SCI - a Chinese VC and several private investors.      

Naturally, each investor has his own distinct agenda. There was a lively discussion as to how to manage these agendas in a transparent and effective way, while creating value for all investors in the incubator.


Digital Health News - for the first time, the FDA has approved a digital pill: medication embedded with a sensor that can tell doctors whether, and when, patients take their medicine.

The approval, announced earlier in November, marks a significant advance in the growing field of digital devices designed to monitor medicine-taking and to address the expensive, longstanding problem that millions of patients do not take drugs as prescribed. Experts estimate that so-called nonadherence or noncompliance to medication costs about $100 billion a year, much of it because patients get sicker and need additional treatment or hospitalization.

This is how the MYCITE system works:

  • The first FDA-approved digital medicine system, is comprised of a tablet embedded at the point of manufacture with an IEM sensor. This IEM sensor is the size of a grain of sand, and is made up of ingredients found in food.
  • The IEM sensor activates when in contact with stomach fluid and communicates to a wearable sensor, called the MYCITE Patch. The IEM sensor is then digested and eliminated from the body.
  • The MYCITE Patch detects and records the date and time of the ingestion of the tablet, as well as, certain physiological data such as activity level, and communicates this and the tablet ingestion data to the MYCITE APP on a compatible mobile device.
  • The MYCITE APP allows individuals to review their objective medication ingestion and daily activity level, as well as enter their mood and rest. They can also invite others to view their data.
  • Web-based dashboards are provided to healthcare providers and caregivers. These dashboards give the healthcare provider the ability to display the individual’s drug ingestion patterns over time. With patient consent, selected members of the family and care team can also access this information, as well as, the individual’s daily activity level and self-reported mood and rest.

Read More..



eHealth Ventures Annoounces it's 2nd Innovation Contest, Partering with MK&M
As in last March, we are holding another contest for disruptive companies / entrepreneurs. We are keeping the successful format from last year, but this time - eHV is partnering with the Morris Kahn & Maccabi Research and Innovation Institute (MK&M), owner of one of the largest medical databases in the world - with data for more than 2 million patents for over 20 years (!).

Again - the event is designed around innovation and the entrepreneurs behind it - with a start-up contest, major prizes, top level speakers and good food and drinks. 

As you all operate within wide ecosystems, feel free to forward this to your networks within the digital health space – aimed mainly at companies / products / technologies linked to usage of Big Data. Details and application for the contest are below.

All applicants will receive:

Exposure to MK&M and eHV management teams and multinational partners

Finalists will present on stage to a “Shark Tank” of investor / partner / expert reps.

Valuable prizes to the winner

We invite all game-changing entrepreneurs, developing products / technologies / companies involving Big Data in Digital Health and aiming to change the way medicine will be delivered - to send us an application.

Applications must include:

Executive Summary (2 pages max.)

Slide Deck (10 slides max.)

Scientific basis (if applicable) - 2 publications max

CV’s of founders / team (3 max.)

Deadline for applications:     Jan. 15th, 2018 at 12:00

Send Applications to http://bit.ly/Apply2BigData

To change your subscription, click here.